204 related articles for article (PubMed ID: 33216365)
1. Sex differences in outcomes in multiple myeloma.
Derman BA; Langerman SS; Maric M; Jakubowiak A; Zhang W; Chiu BC
Br J Haematol; 2021 Feb; 192(3):e66-e69. PubMed ID: 33216365
[No Abstract] [Full Text] [Related]
2. Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores.
Engelhardt M; Dold SM; Ihorst G; Zober A; Möller M; Reinhardt H; Hieke S; Schumacher M; Wäsch R
Haematologica; 2016 Sep; 101(9):1110-9. PubMed ID: 27479825
[TBL] [Abstract][Full Text] [Related]
3. Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis.
Derman BA; Jasielec J; Langerman SS; Zhang W; Jakubowiak AJ; Chiu BC
Blood Cancer J; 2020 Aug; 10(8):80. PubMed ID: 32770051
[TBL] [Abstract][Full Text] [Related]
4. Changing survival of people with myeloma and end stage kidney disease: A cohort study using Australian and New Zealand dialysis and transplant registry 1963-2013.
Webster AC; Irish AB; Kelly PJ
Nephrology (Carlton); 2018 Mar; 23(3):217-225. PubMed ID: 28004444
[TBL] [Abstract][Full Text] [Related]
5. The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.
Sigurdardottir EE; Turesson I; Lund SH; Lindqvist EK; Mailankody S; Korde N; Björkholm M; Landgren O; Kristinsson SY
JAMA Oncol; 2015 May; 1(2):168-74. PubMed ID: 26181017
[TBL] [Abstract][Full Text] [Related]
6. Progression of a solitary plasmacytoma to multiple myeloma. A population-based registry of the northern Netherlands.
de Waal EG; Leene M; Veeger N; Vos HJ; Ong F; Smit WG; Hovenga S; Hoogendoorn M; Hogenes M; Beijert M; Diepstra A; Vellenga E
Br J Haematol; 2016 Nov; 175(4):661-667. PubMed ID: 27605358
[TBL] [Abstract][Full Text] [Related]
7. Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma.
Ozaki S; Handa H; Saitoh T; Murakami H; Itagaki M; Asaoku H; Suzuki K; Isoda A; Matsumoto M; Sawamura M; Konishi J; Sunami K; Takezako N; Hagiwara S; Kuroda Y; Chou T; Nagura E; Shimizu K
Blood Cancer J; 2015 Sep; 5(9):e349. PubMed ID: 26383822
[No Abstract] [Full Text] [Related]
8. A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients.
Engelhardt M; Domm AS; Dold SM; Ihorst G; Reinhardt H; Zober A; Hieke S; Baayen C; Müller SJ; Einsele H; Sonneveld P; Landgren O; Schumacher M; Wäsch R
Haematologica; 2017 May; 102(5):910-921. PubMed ID: 28154088
[TBL] [Abstract][Full Text] [Related]
9. Conditioning-based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991-2012) on behalf of EBMT CMWP.
Hayden PJ; Iacobelli S; Pérez-Simón JA; van Biezen A; Minnema M; Niittyvuopio R; Schönland S; Meijer E; Blaise D; Milpied N; Márquez-Malaver FJ; Veelken JH; Maertens J; Michallet M; Cammenga J; N'Guyen S; Niederwieser D; Hunault-Berger M; Bourhis JH; Passweg J; Bermudez A; Chalandon Y; Yakoub-Agha I; Garderet L; Kröger N
Eur J Haematol; 2020 Mar; 104(3):181-189. PubMed ID: 31737951
[TBL] [Abstract][Full Text] [Related]
10. The effect of marital status on the survival of patients with multiple myeloma.
Tang L; Pan Z; Zhang X
Hematology; 2022 Dec; 27(1):187-197. PubMed ID: 35068385
[TBL] [Abstract][Full Text] [Related]
11. The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population-based study.
Gregersen H; Vangsted AJ; Abildgaard N; Andersen NF; Pedersen RS; Frølund UC; Helleberg C; Broch B; Pedersen PT; Gimsing P; Klausen TW
Cancer Med; 2017 Jul; 6(7):1807-1816. PubMed ID: 28639741
[TBL] [Abstract][Full Text] [Related]
12. Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial.
Gimsing P; Carlson K; Turesson I; Fayers P; Waage A; Vangsted A; Mylin A; Gluud C; Juliusson G; Gregersen H; Hjorth-Hansen H; Nesthus I; Dahl IM; Westin J; Nielsen JL; Knudsen LM; Ahlberg L; Hjorth M; Abildgaard N; Andersen NF; Linder O; Wisløff F
Lancet Oncol; 2010 Oct; 11(10):973-82. PubMed ID: 20863761
[TBL] [Abstract][Full Text] [Related]
13. Risk of disease recurrence and survival in patients with multiple myeloma: A German Study Group analysis using a conditional survival approach with long-term follow-up of 815 patients.
Schinke M; Ihorst G; Duyster J; Wäsch R; Schumacher M; Engelhardt M
Cancer; 2020 Aug; 126(15):3504-3515. PubMed ID: 32459378
[TBL] [Abstract][Full Text] [Related]
14. Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of ΔSUVmax in the FDG-Avid Patients of the IMAJEM Study.
Bailly C; Carlier T; Jamet B; Eugene T; Touzeau C; Attal M; Hulin C; Facon T; Leleu X; Perrot A; Garderet L; Macro M; Caillot D; Moreau P; Kraeber-Bodéré F; Bodet-Milin C
Clin Cancer Res; 2018 Nov; 24(21):5219-5224. PubMed ID: 30068709
[No Abstract] [Full Text] [Related]
15. Incidence of spinal disease and role of spinal radiotherapy in multiple myeloma.
Sharma AM; Sackett M; Bueddefeld D; Lambert P; Dubey A; Wadhwa V; Kotb R; Ahmed N
Curr Oncol; 2018 Dec; 25(6):e539-e544. PubMed ID: 30607121
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of patients with simultaneous diagnosis of chronic lymphocytic leukaemia/small lymphocytic lymphoma and multiple myeloma.
Ailawadhi S; Dholaria BR; Khurana S; Sher T; Alegria V; Paulus A; Ailawadhi M; Mehta A; Chanan-Khan A; Roy V
Br J Haematol; 2019 Apr; 185(2):347-350. PubMed ID: 29978498
[No Abstract] [Full Text] [Related]
17. Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE.
Goldschmidt H; Baertsch MA; Schlenzka J; Becker N; Habermehl C; Hielscher T; Raab MS; Hillengass J; Sauer S; Müller-Tidow C; Luntz S; Jauch A; Hose D; Seckinger A; Brossart P; Goerner M; Klein S; Schmidt-Hieber M; Reimer P; Graeven U; Fenk R; Haenel M; Martin H; Lindemann HW; Scheid C; Nogai A; Salwender H; Noppeney R; Besemer B; Weisel K;
Leukemia; 2021 Apr; 35(4):1134-1144. PubMed ID: 32694619
[TBL] [Abstract][Full Text] [Related]
18. Absolute lymphocyte count as predictor of overall survival for patients with multiple myeloma treated with single autologous stem cell transplant.
Jimenez-Zepeda VH; Reece DE; Trudel S; Chen C; Franke N; Winter A; Tiedemann R; Kukreti V
Leuk Lymphoma; 2015; 56(9):2668-73. PubMed ID: 25573201
[TBL] [Abstract][Full Text] [Related]
19. Predictors of inferior clinical outcome in patients with standard-risk multiple myeloma.
Badar T; Srour S; Bashir Q; Shah N; Al-Atrash G; Hosing C; Popat U; Nieto Y; Orlowski RZ; Champlin R; Qazilbash MH
Eur J Haematol; 2017 Mar; 98(3):263-268. PubMed ID: 27862330
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
